Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBT (2016 - 2025)

Abeona Therapeutics has reported EBT over the past 15 years, most recently at -$20.7 million for Q4 2025.

  • Quarterly results put EBT at -$20.7 million for Q4 2025, down 122.48% from a year ago — trailing twelve months through Dec 2025 was $62.6 million (up 231.93% YoY), and the annual figure for FY2025 was $71.3 million, up 211.84%.
  • EBT for Q4 2025 was -$20.7 million at Abeona Therapeutics, down from -$20.4 million in the prior quarter.
  • Over the last five years, EBT for ABEO hit a ceiling of $124.3 million in Q2 2025 and a floor of -$46.7 million in Q4 2021.
  • Median EBT over the past 5 years was -$14.3 million (2021), compared with a mean of -$8.9 million.
  • Biggest five-year swings in EBT: plummeted 194.85% in 2021 and later soared 1578.98% in 2025.
  • Abeona Therapeutics' EBT stood at -$46.7 million in 2021, then skyrocketed by 71.9% to -$13.1 million in 2022, then fell by 1.56% to -$13.3 million in 2023, then surged by 30.22% to -$9.3 million in 2024, then plummeted by 122.48% to -$20.7 million in 2025.
  • The last three reported values for EBT were -$20.7 million (Q4 2025), -$20.4 million (Q3 2025), and $124.3 million (Q2 2025) per Business Quant data.